The global short-acting beta-agonists market was anticipated to reach a valuation of US$ 675 Million in the year 2022. With a robust CAGR of 9.1% from 2023 to 2033, this market is expected to reach US$ 736.43 Million by 2023 and US$ 1759.45 Million by 2033.
Short-acting beta-agonists (SABAs) are medications that act quickly to treat or prevent the signs and symptoms of asthma and COPD. Rescue inhalers are another name for these drugs. Better airflow is made possible by the relaxation of the lungs' muscles and the maintenance of open airways. Such benefits of these medications are aiding the market growth and the same trend is expected during the forecast period of 2023 to 2033.
The World Health Organization (WHO) estimates that 3.28 million people worldwide will pass away from COPD in 2020. Globally, chronic obstructive pulmonary disease (COPD) ranks third in terms of fatality rates. Throughout the projected period, the market for short-acting beta-agonists is anticipated to expand at a CAGR of over 9%. LABAs, which are inhaled medications, are used to treat lung disorders such as asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), and others. The market is expected to expand as a result of the rising frequency of lung disorders throughout the world. Those who were reared in metropolitan areas or who presently live there are more likely to suffer from these ailments.
Also, adults as well as kids who are overweight or obese have an increased chance of developing respiratory disorders. The expansion of the worldwide market is anticipated to be driven by the rising incidence of obesity and the expanding urban population. The population of cities worldwide has considerably expanded, going from 751 million in 1950 to over 4.7 billion in 2021, as reported by the United Nations (UN). Also, it is anticipated that the increased production of novel pharmaceuticals and medicines would spur market expansion throughout the projection period.
Due to the rising incidence of asthma amongst children in the area, the North American market is anticipated to have the biggest market share in the worldwide market during the forecast period. For instance, asthma is the most common chronic ailment among children in the area, affecting about 5.5 million children under the age of 18 in the USA. Major pharmaceutical firms' presence in the area and rising healthcare spending will also be prominent drivers of market expansion throughout the anticipated timeframe. The Centers for Medicare & Medicaid Services (CMS) estimate that in 2021, USA health spending will have climbed by 9.7% and will total USD 4.2 trillion (or USD 12,530 per person).
Several new drug discoveries and developments have also been propelling the growth in the global short-acting beta-agonists market. As an illustration, the pricey medication albuterol is employed to alleviate or avoid bronchospasm in people with bronchitis, asthma, emphysema, as well as other lung conditions. This medication is also used to stop wheezing brought on by physical activity. Comparable medications don't compare to this drug's popularity. Both the brand name and generic forms of proair hfa are offered. Another is LEVALBUTEROL, which is used to treat lung conditions including asthma, in which the lungs' airways constrict and cause breathing issues or wheezing (bronchospasm). It functions by widening the lungs' airways, which facilitates breathing. It is frequently referred to as a rescue or fast-relief inhaler. Such drug developments will open up new opportunities for the global short-acting beta-agonists market during the forecast period.
| Data Point | Key Statistics |
|---|---|
| Expected Market value in 2023 | US$ 736.43 Million |
| Expected Market value in 2033 | US$ 1759.45 Million |
| Growth Rate (2023 to 2033) | 9.1% from 2023 to 2033 |
Short-acting beta-agonists (bronchodilators) are the drugs used to treat respiratory diseases, mostly used for treating asthma. Short-acting beta-agonists are known as a quick-acting and relieving medication from asthma attacks, as it helps to rapidly open the airways.
It also provides instant relief to manage both acute and stable exacerbations of chronic obstructive pulmonary disease. The most commonly prescribed drug is salbutamol in the short-acting beta-agonists market. The short-acting beta-agonists market is likely to grow with the increasing number of patients suffering from asthma and chronic obstructive pulmonary disease.
Pandemic coronavirus is disrupting all the industries. The novel coronavirus is developing various opportunities in the short-acting beta-agonists market. People having any kind of pulmonary disorders are more likely to get coronavirus disease.
Since a huge number of population is suffering from asthma and chronic obstructive pulmonary disease across the globe, it has led to an increase in the demand to manage asthma and chronic obstructive pulmonary disease which in turn is driving the growth of the short-acting beta-agonists market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Increasing prevalence of asthma and chronic diseases such as chronic obstructive pulmonary diseases are driving the growth of the short-acting beta-agonists market. The emergence of various drugs to treat severe asthma and novel combination therapies are expected to surge the growth of the short-acting beta-agonists market.
Furthermore, advancements in the technologies and also product innovation are leading to increased demand for short-acting beta-agonists. However, the exclusivity of branded drugs and expiry of patents are restricting the growth of the short-acting beta-agonists market.
Based on the dosage form, solution and injectable are the most widely used dosage form in the short-acting beta-agonists market. Based on the application, short-acting beta-agonists are mainly used in the treatment of asthma due to the increasing demand to manage severe asthma attacks.
Based on the distribution channel, hospital pharmacies are the most profitable segment in the short-acting beta-agonists market. Short-acting beta-agonists are the choice of drug in the market for treating asthma. They usually show their result within a few minutes to treat the symptoms such as wheezing, chest tightness, and shortness of breathing.
Commonly prescribed short-acting beta-agonists are albuterol, pirbuterol, levalbuterol. Apart from this, short-acting beta-agonists have several side effects such as headaches, suddenly noticeable heartbeats, trembling in the hands, muscle cramps, and others. Scientists are continuously working to reduce the side effects of short-acting beta-agonists in treating asthma.
Principal Consultant
North America and Europe are expected to dominate the global short-acting beta-agonists market, owing to the higher adoption of drugs and advancement in drug discovery in the regions. Also, high prevalence rate of asthma and chronic obstructive pulmonary disease are expected to increase the growth of the short-acting beta-agonists market in these regions.
Increase in healthcare expenditure in the developing region like Asia-Pacific is expected to push the global short-acting beta-agonists market growth over the forecast period. Also, rising population in countries like India and China is expected to further drive the growth of the market in these regions. In Middle East and Africa, the short-acting beta-agonist market is estimated to expand due to increasing asthma patients and increasing air pollution.
Some of the market participants in the global short-acting beta-agonists market identified across the value chain include:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Explore Healthcare Insights
View Reports
Short-Acting Beta-Agonists Market
